Insulin degludec/liraglutide has proven to be superior to insulin glargine in hemoglobin A1c reduction, risk of hypoglycemia, and weight reduction in the DUAL V study. This result of the open-label DUAL V trial was reported at the Annual Meeting of the European Association for the Study of Diabetes 2015.
According to a new research, the risk of pancreatic cancer was not elevated with incretin-based drugs compared with other glucose-lowering therapies.
Glyburide is associated with an increased risk for cancer compared with other diabetes drugs of the sulfonylurea class, new research suggests. Previous observational studies have linked the use of sulfonylureas in general to an increased risk of cancer, but only a few studies have examined the association by type of sulfonylurea, the authors explain.
Another trial of extended clopidogrel has done little to settle the confusion about how long dual antiplatelet therapy should be continued following drug-eluting–stent (DES) placement, with one commentator saying the studies available on this topic were like “the blind leading the deaf.”
Both CV-event rates and prevalence of serious gastrointestinal complications were surprisingly low in people without heart disease taking either celecoxib (Celebrex, Pfizer) or traditional nonsteroidal anti-inflammatory agents (NSAIDs) for arthritis, say researchers from a randomized trial reported here at the European Society of Cardiology (ESC) 2015 Congress.
Combining two diuretics, amiloride and hydrochlorothiazide (HCTZ), results in a significant reduction in blood pressure, more so than when each drug is used alone, and has the beneficial effect of neutralizing undesirable changes in blood glucose and potassium, according to the results of a new study.
Antibiotic use was associated with an increased risk for type 2 diabetes in a new population-based, case-control study, published online August 27, 2015 in the Journal of Clinical Endocrinology and Metabolism by Kristian Hallundback Mikkelsen, MD, a PhD student at the Center for Diabetes Research, Gentofte Hospital, University of Copenhagen (Hellerup, Denmark) and colleagues.
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. We have added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) […]